Comparative Pharmacology
Head-to-head clinical analysis: KYTRIL versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYTRIL versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
KYTRIL vs ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist, blocking serotonin binding at vagal nerve terminals and central nervous system chemoreceptor trigger zone.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. It blocks the action of serotonin at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, thereby preventing nausea and vomiting. Dextrose provides caloric support.
2 mg orally once daily or 1 mg intravenously 30 minutes before chemotherapy. For prevention of nausea/vomiting, 2 mg orally 1 hour before chemotherapy or 1 mg IV over 30 seconds.
4 mg IV or IM every 8 hours as needed; for prevention of chemotherapy-induced nausea and vomiting, 0.15 mg/kg IV up to 16 mg per dose, infused over 15 minutes, given 30 minutes before chemotherapy, then repeat at 4 and 8 hours after first dose, or as a single 32 mg IV dose over 15 minutes immediately before chemotherapy.
None Documented
None Documented
Terminal elimination half-life is 5.9 hours in healthy young adults; in cancer patients, it may be prolonged to 10-12 hours. Clinical context: supports twice-daily dosing for chemotherapy-induced nausea and vomiting (CINV) prophylaxis.
Terminal elimination half-life is approximately 3–4 hours in adults, though may be prolonged to 5–8 hours in severe hepatic impairment (Child-Pugh class C) or elderly patients.
Approximately 16% of the dose is excreted unchanged in urine; 44% is eliminated as metabolites (mainly 5-hydroxygranisetron) in urine, and 33% is excreted in feces as metabolites. Renal clearance accounts for about 30% of total clearance.
Primarily hepatic metabolism (~95%) via CYP1A2, CYP2D6, and CYP3A4; less than 10% excreted unchanged in urine. Fecal excretion accounts for ~20% of metabolites.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)